Lexicon Genetics of The Woodlands, Texas, has altered over one-third of all genes in the mouse genome, which could provide useful information about the human genome for drug discovery.
The company is collecting knockout mouse clones, which are being used by Lexicon and its partners to identify which genes are valuable for drug discovery to treat human disease, said Arthur Sands, Lexicon’s president and CEO.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
